Needham & Company LLC restated their hold rating on shares of Gilead Sciences, Inc. (NASDAQ:GILD) in a research report report published on Monday.

A number of other brokerages have also issued reports on GILD. Maxim Group reiterated a hold rating on shares of Gilead Sciences in a research report on Thursday, July 27th. BMO Capital Markets reiterated an outperform rating and set a $82.00 target price (up previously from $72.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. Zacks Investment Research lowered Gilead Sciences from a buy rating to a hold rating in a report on Tuesday, July 18th. BidaskClub upgraded Gilead Sciences from a sell rating to a hold rating in a report on Monday, July 24th. Finally, J P Morgan Chase & Co restated an overweight rating and issued a $82.00 price objective on shares of Gilead Sciences in a report on Tuesday, July 4th. Eleven equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $80.83.

Gilead Sciences (GILD) traded up 1.11% during mid-day trading on Monday, reaching $75.52. 7,062,529 shares of the company were exchanged. The stock has a 50 day moving average of $72.97 and a 200-day moving average of $68.86. Gilead Sciences has a one year low of $63.76 and a one year high of $82.07. The stock has a market capitalization of $98.62 billion, a price-to-earnings ratio of 8.20 and a beta of 1.21. Gilead Sciences also was the recipient of some unusual options trading on Monday. Investors purchased 19,878 put options on the company. This represents an increase of approximately 209% compared to the typical daily volume of 6,434 put options.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm had revenue of $7.14 billion for the quarter, compared to analyst estimates of $6.35 billion. During the same quarter last year, the firm posted $3.08 EPS. The business’s revenue was down 8.2% on a year-over-year basis. On average, equities analysts expect that Gilead Sciences will post $8.74 earnings per share for the current fiscal year.

WARNING: “Gilead Sciences, Inc. (GILD) Given “Hold” Rating at Needham & Company LLC” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.watchlistnews.com/gilead-sciences-inc-gild-given-hold-rating-at-needham-company-llc/1530186.html.

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be issued a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.78%. Gilead Sciences’s dividend payout ratio is presently 22.58%.

In other news, EVP Gregg H. Alton sold 5,000 shares of Gilead Sciences stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $71.06, for a total transaction of $355,300.00. Following the transaction, the executive vice president now owns 102,988 shares in the company, valued at approximately $7,318,327.28. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $75.86, for a total value of $5,563,041.38. Following the transaction, the insider now owns 3,199,969 shares in the company, valued at approximately $242,749,648.34. The disclosure for this sale can be found here. In the last quarter, insiders have sold 206,666 shares of company stock worth $15,223,184. Insiders own 1.30% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of GILD. Hall Laurie J Trustee increased its stake in shares of Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 250 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its stake in shares of Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 1,400 shares during the last quarter. Dubuque Bank & Trust Co. increased its stake in shares of Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 267 shares during the last quarter. Penserra Capital Management LLC increased its stake in shares of Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 144 shares during the last quarter. Finally, Webster Bank N. A. increased its stake in shares of Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 624 shares during the last quarter. Institutional investors and hedge funds own 74.04% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.